Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Wyeth/Takeda's Enbrel will sustain its first-to-market advantage over other biologics and continue to dominate the psoriasis market through 2011. However, Abbott/Eisai's Humira will challenge Enbrel's leading position and reach more than $1 billion in sales by 2016.

The new Pharmacor report entitled Psoriasis finds that Humira, which will achieve a 38% annual growth rate during the 2006 to 2016 study period, and Enbrel will be the key biologics driving growth in the psoriasis drug market. The report also finds that, despite evidence of unsurpassed efficacy and an ability to induce long-term remission, the initial uptake of the novel biologics Centocor/Janssen-Cilag's ustekinumab and Abbott's ABT-874 will be affected by safety concerns and reimbursement hurdles.

Market growth in the treatment of psoriasis will come primarily from premium priced biologics as pharmacoeconomic considerations play an increasing role in the uptake of emerging drugs. Amid escalating health care costs in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, payers are likely to limit access to premium priced agents in dermatology.

"None of the emerging oral agents are positioned to change the trend of decreasing sales for nonbiologic systemic agents," said Irene Koulinska, analyst at Decision Resources. "Because of the high level of dissatisfaction with current treatment options and low use of systemic therapies, significant opportunities remain for marketers of novel topical and systemic agents."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563  

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011

View Now